Welcome to our dedicated page for AKSO HEALTH GROUP news (Ticker: AHG), a resource for investors and traders seeking the latest updates and insights on AKSO HEALTH GROUP stock.
Akso Health Group (NASDAQ: AHG) is a medical technology and healthcare services company that has transitioned from social e-commerce in China into healthcare equipment, medical devices, oncology services, and online medical consultations. Its news flow reflects this shift, covering developments in AI-powered healthcare, Internet clinics, and its listed status on the Nasdaq Capital Market.
News about Akso Health Group includes announcements on the integration of DeepSeek’s artificial intelligence technology to enhance AI-powered medical consultation and diagnosis. The company reports using multimodal large-scale models, deep learning frameworks, and big data processing to upgrade its AI diagnosis system and to build an AI-powered medical assistant that supports doctors with record retrieval, case analysis, and treatment recommendations.
Investors and observers can also find updates on Akso Health Group’s online clinic initiatives, such as its plan to invest in Deyihui, an online clinic in China, and its indirect acquisition of equity interests in Tianjin Deyihui Internet Hospital Co., Ltd. and Tianjin Deyihui Clinic Co., Ltd. These items highlight the company’s participation in Internet smart healthcare and chronic disease management through online consultations.
Regulatory and listing-related announcements form another important category of news, including Nasdaq notifications about minimum bid price requirements, stockholders’ equity thresholds, and filing timeliness. Together, these news items provide context on both Akso Health Group’s operational direction in healthcare and its status as a publicly traded company. Readers interested in AHG can use this news page to follow company statements on AI in healthcare, medical devices, online medical services, and Nasdaq compliance matters.
Akso Health (NASDAQ: AHG) launched an exploratory global patient support initiative and a strategic cooperation with Nanning Duoling Research Institute on Feb 3, 2026. The program aims to coordinate medical resources to provide free in-hospital treatment plans for up to 10,000 eligible patients through an integrated "TCM practice + modern medical technology" model.
The plan connects planned radiation oncology centers, targeted drugs, and remote consultation teams, with Nanning Duoling supplying diagnostic technologies, reagents, lab testing, and expert teams. Participation is limited, phased, conditional on eligibility, institutional qualifications, regulatory requirements, and funding.
Akso Health Group (NASDAQ: AHG) announced the integration of DeepSeek's artificial intelligence technology to enhance its healthcare services. The company will utilize DeepSeek's multimodal large-scale models, deep learning frameworks, and big data processing capabilities to upgrade its AI-powered diagnosis system.
The enhanced system will integrate patient text descriptions, medical imaging, and laboratory test results to provide more accurate diagnoses and personalized treatment recommendations. AHG is also developing an AI-powered medical assistant to support doctors in retrieving patient records, analyzing similar cases, and recommending treatment plans.
The company focuses on implementing human-centric AI interactions to ensure a more natural and empathetic user experience, aiming to reduce patient anxiety and optimize consultation experiences. AHG plans to continue exploring AI applications in research and development, health management, and telemedicine.
Summary not available.
Summary not available.
Akso Health Group (NASDAQ: AHG) announced it received a notification from Nasdaq on February 28, 2023, indicating it is non-compliant with the minimum stockholders' equity requirement of $10 million. As of September 30, 2022, Akso reported approximately $9.9 million in stockholders' equity. While this notification does not immediately affect its listing, Akso has until April 14, 2023, to propose a compliance plan. If accepted, Nasdaq may grant an extension of up to 180 days, extending the compliance deadline to August 27, 2023.
Akso continues to operate within the social e-commerce and healthcare equipment sectors, previously known as Xiaobai Maimai.
Akso Health Group (NASDAQ: AHG) announced that it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of US$1.00 per share, effective from October 26, 2022. The company's shares had fallen below this threshold for 30 consecutive business days. Akso Health has until April 24, 2023, to regain compliance. The company is exploring options like a reverse share split but asserts that its business operations remain unaffected. Furthermore, Nasdaq accepted the company’s plan for compliance regarding the delinquent filing of its Annual Report on Form 20-F.
Akso Health Group (NASDAQ: AHG) announced it received a notification from Nasdaq on August 16, 2022, for not complying with timely filing requirements, as it has not filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2022. The Company has 60 days to address this deficiency or submit a plan to regain compliance by October 17, 2022. The notification does not affect the Company's business operations. Akso Health also plans to expand into cancer therapy services, including opening 100 radiation oncology centers in the U.S.
FAQ
What is the current stock price of AKSO HEALTH GROUP (AHG)?
What is the market cap of AKSO HEALTH GROUP (AHG)?
